• News
  • Health

CURx Pharmaceuticals in license agreement with Gilead

San Diego-based CURx Pharmaceuticals has entered into a global license agreement with Gilead Sciences Inc. for the development of Fosfomycin: Tobramycin for Inhalation to treat Pseudomonas aeruginosa lung infection in cystic fibrosis patients.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!